December 2001
Worldwide Biotech;Dec2001, Vol. 13 Issue 12, p1
Trade Publication
Focuses on the marketing of the generic equivalent of Bayer's ciprofloxacin brand by the Spanish subsidiary of Bentley Pharmaceuticals Inc. named Laboratorios Davur. Implications of Bentley's marketing into the U.S.; Challenges in entering the U.S. market; Purpose of Bentley's efforts.


Related Articles

  • Bentley obtains Spain drug OK.  // New Hampshire Business Review;12/01/2000, Vol. 22 Issue 25A, p21 

    Reports on the approval of the Spanish Ministry of Health for Bentley Pharmaceuticals Inc. to produce and market a generic version of the drug omeprazole in Spain.

  • Perrigo, Bentley To Co-Develop Generic Rx Drugs. Emrich, Anne Bond // Grand Rapids Business Journal;11/8/2004, Vol. 22 Issue 46, p7 

    Reports on an agreement entered into by Perrigo Co. and Exeter, New Hampshire-based Bentley Pharmaceuticals Inc. regarding the development and marketing of generic prescription drugs in the U.S. market. Role of Bentley in the agreement; Significance of the agreement to Bentley; Objective of...

  • Bayer Increases Cipro Production On Mushrooming Demand in US.  // Chemical Market Reporter;10/22/2001, Vol. 260 Issue 15, p2 

    Reports on the increase in production of the antibiotic ciprofloxacin by Bayer AG as of October 22, 2001. Reason for the increase; Plans of the company to increase production of the antibiotic; Antibiotics effective for treating anthrax.

  • CF search.  // Drug Topics;4/22/96, Vol. 140 Issue 8, p24 

    Reports that Bayer AG is seeking approval from the Food and Drug Administration for the use of Cipro (ciprofloxacin) to treat acute pulmonary infections in children and adolescents with cystic fibrosis.

  • India sets precedent for overcoming drug price barriers. Bateman, Chris // CME: Continuing Medical Education;Apr2012, Vol. 30 Issue 4, p148 

    The article reports on a landmark case where the Indian Patent Office on March 12, 2012 issued the first-ever compulsory license to a generic drug manufacturer. The license ended Bayer's monopoly in India over a kidney and liver cancer drug. This is the first time India's patent law is utilized...

  • India Rejects Bayer Plea against Cancer Drug. GEORGE, NIRMALA // India -- West;3/15/2013, Vol. 38 Issue 17, pA38 

    The article reports that the Intellectual Property Appellate Board in India has rejected the German drug maker, Bayer AG's appeal of the 2012 ruling on March 4, 2013 to halt the production of a cheaper generic version of a patented cancer drug.

  • Bentley drug wins UK approval.  // New Hampshire Business Review;12/23/2005, Vol. 27 Issue 27, p42 

    The article reports on the approval of the British Medicines and Healthcare Products Regulatory Agency of the marketing of the generic antacid drugs of Bentley Pharmaceuticals Inc. in the country. The agency has grant its approval on the 15 and 30 mg dosages of lansoprazole capsules, acid-pump...

  • Bentley Stays Outside the Box.  // Pharmaceutical Executive;Jun2004, Vol. 24 Issue 6, p34 

    Interviews James Murphy, chief executive officer of Europe-based Bentley Pharmaceuticals Inc. Plan to import generics into the United States; Reason for concentrating on drug delivery; Advantages of working in Spain. INSET: At Home at Bentley.

  • Bush Administration Talks to Bayer About Relaxing Its Antibiotic Cipro Patent.  // Chemical Market Reporter;10/22/2001, Vol. 260 Issue 15, p4 

    Reports that the United States government requested Bayer AG to relax its patent on the antibiotic Cipro, or ciprofloxacin, an oral treatment of anthrax. Response of Bayer to anthrax cases in the country; Measures undertaken by the government to boost emergency drug stockpiles; Average...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics